Hydrogel membrane for adhesion prevention
A biocompatible membrane comprised of alginate and hyaluronate. The membrane may be used to prevent unwanted scarring after surgery. The tissue adherence and the rate of bioresorption of the membrane may be modified through an external stimulus comprising a sequestering agent and a viscosity modifier.
1. A kit comprising:
uncrosslinked hyaluronic acid and crosslinked alginate both included in a hydrogel film; and
a calcium chelator;
wherein (a) the alginate is crosslinked with calcium, (b) the hydrogel film is flat and includes a width, a length, and a thickness that is less than the width and the length, and (c) the hydrogel film is configured so bioresorbability of the hydrogel film increases in response to applying the calcium chelator to the hydrogel film.
2. The kit of claim 1 , wherein the calcium chelator is configured to disrupt calcium crosslinks within the hydrogel film.
3. The kit of claim 1 , wherein the calcium chelator is selected from the group consisting of citrate, EDTA, EGTA, and BAPTA, or a phosphate.
4. The kit of claim 2 , wherein concentration of the calcium chelator is 0.05 to 1.0 molar.
5. The kit of claim 2 comprising a thickening agent.
6. The kit of claim 5 wherein the thickening agent includes sodium hyaluronate.
7. The kit of claim 6 , wherein the thickening agent is configured to increase viscosity of the calcium chelator.
8. The kit of claim 1 wherein the hydrogel film consists essentially of hyaluronic acid and alginate.
9. The kit of claim 8 , wherein dry weight of the hydrogel film is at least 1% and no more than 33% hyaluronic acid.
10. The kit of claim 1 , wherein the hydrogel film comprises:
a first hydrogel layer comprising the uncrosslinked hyaluronic acid and the crosslinked alginate; and
a second hydrogel layer comprising collagen and hyaluronic acid.
11. The kit of claim 10 , wherein the first hydrogel layer is monolithic, the second hydrogel layer is monolithic but not monolithic with the first hydrogel layer, and the first and second hydrogel layers are covalently bound to one another.
12. The kit of claim 11 , wherein the hydrogel film comprises:
a third hydrogel layer comprising additional uncrosslinked hyaluronic acid and additional crosslinked alginate;
wherein the third hydrogel layer is monolithic but not monolithic with the second hydrogel layer, the third and second hydrogel layers are covalently bound to one another, and the second hydrogel layer is between the first and third hydrogel layers.
13. The kit of claim 1 , wherein the alginate is crosslinked around the uncrosslinked hyaluronic acid.
14. The kit of claim 1 wherein the hydrogel film comprises a therapeutic agent selected from the group comprising a drug, a pharmaceutical agent, a peptide, a protein, a medicine, a hormone, and a macromolecule.
15. The kit of claim 14 , wherein the hydrogel film is configured so the hydrogel film's release rate for the therapeutic agent increases in response to applying the calcium chelator to the hydrogel film.
16. The kit of claim 15 , wherein the alginate is crosslinked around the therapeutic agent.
17. The kit of claim 14 , wherein the hydrogel film is configured so the hydrogel film's release rate for the therapeutic agent increases in response to increasing the amount of the uncrosslinked hyaluronic acid in the hydrogel film.
18. The kit of claim 1 comprising a therapeutic agent selected from the group consisting of a drug, a pharmaceutical agent, a peptide, a protein, a medicine, a hormone, or a macromolecule.
19. The kit of claim 1 , wherein the hydrogel film is configured so mucoadhesiveness for the hydrogel film increases in response to applying the calcium chelator to the hydrogel film.
20. The kit of claim 1 , wherein the hydrogel film is configured to increase in transparency in response to applying the calcium chelator to the hydrogel film.
21. The kit of claim 1 , wherein the hydrogel film has a thickness of between 5 and 30 micrometers.
22. A kit comprising:
a hydrogel film comprising crosslinked alginate that is crosslinked around uncrosslinked hyaluronic acid to entrap the uncrosslinked hylalunonic acid within the crosslinked alginate; and
a sequestering agent;
wherein (a) the alginate is crosslinked with a multivalent cation, (b) the hydrogel film is planar, (c) the hydrogel film is configured so its bioresorbability increases in response to applying the sequestering agent to the hydrogel film, and (d) the sequestering agent is configured to sequester the multivalent cation.
23. The kit of claim 22 , wherein the hydrogel film comprises:
a first hydrogel layer comprising the uncrosslinked hyaluronic acid and the crosslinked alginate; and
a second hydrogel layer comprising a therapeutic agent selected from the group comprising a drug, a pharmaceutical agent, a peptide, a protein, a medicine, a hormone, and a macromolecule;
wherein (a) the first hydrogel layer is monolithic, (b) the second hydrogel layer is monolithic but not monolithic with the first hydrogel layer, (c) the first and second hydrogel layers are chemically bound to one another, (d) the second hydrogel layer is adhesive, and (e) the first hydrogel layer is anti-adhesive.
24. The kit of claim 22 , wherein the hydrogel film includes a therapeutic agent selected from the group comprising a drug, a pharmaceutical agent, a peptide, a protein, a medicine, a hormone, and a macromolecule; and the hydrogel film is configured so its release rate for the therapeutic agent increases in response to applying the sequestering agent to the hydrogel film.
25. The kit of claim 22 , wherein the hydrogel film is configured so mucoadhesiveness for the hydrogel film increases in response to applying the sequestering agent to the hydrogel film.